Abstract：
The epidermal growth factor receptor (EGFR) family is a class of transmembrane proteins, highly regarded as anticancer targets due to their pivotal role in various malignancies. Standard cancer treatments targeting the ErbB receptors include tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs). Despite their substantial survival benefits, the achievement of curative outcomes is hindered by acquired resistance. Recent advancements in anti-ErbB approaches, such as inhibitory peptides, nanobodies, targeted-protein degradation strategies, and bispecific antibodies (BsAbs), aim to overcome such resistance. More recently, emerging insights into the cell surface interactome of the ErbB family open new avenues for modulating ErbB signaling by targeting specific domains of ErbB partners. Here, we review recent progress in ErbB targeting and elucidate emerging paradigms that underscore the significance of EGF domain-containing proteins (EDCPs) as new ErbB-targeting pathways.
摘要：
表皮生长因子受体(EGFR)家族是一类跨膜蛋白,由于它们在各种恶性肿瘤中的关键作用，因此被视为抗癌靶标。靶向ErbB受体的标准癌症治疗包括酪氨酸激酶抑制剂(TKIs)和单克隆抗体(mAb)。尽管他们有很大的生存益处，获得性抵抗阻碍了治疗结果的实现。反ErbB方法的最新进展，如抑制肽，纳米抗体，靶向蛋白质降解策略，和双特异性抗体（BsAbs），旨在克服这种阻力。最近,对ErbB家族的细胞表面相互作用组的新见解打开了通过靶向ErbB伴侣的特定结构域来调节ErbB信号传导的新途径。这里,我们回顾了ErbB靶向的最新进展,并阐明了新出现的范例,这些范例强调了含EGF结构域蛋白(EDCPs)作为新的ErbB靶向途径的重要性.
